scout

All News

Yervoy

#wrapper { font-family: Arial, Helvetica, sans-serif; font-size: 12px; font-style: normal; background-color: #F2F2F2; width: 960px; padding: 10px 25px 0px 25px;}#isi {margin-left: 300px;}#logo {float: left;}#isi .header{color:#FF9900; font-weight: bold;}#isi-large ul {list-style type: none;}#isi-large li {background: url(dot_list.gif) no-repeat scroll 0.6em transparent; margin: 2;}#isi-large li ul li {background: url(second_liststyle.gif) no-repeat scroll 0.6em transparent; margin: 2; list-style type: none;}#isi-large .text-bold {color:#51626f; font-size: 11px ; font-weight: bold;}#isi-large .text {color:#51626f; font-size: 11px ;}#isi-large .header {color:#e24912; font-size: 12px ; font-weight: bold;}#isi .sub-header{font-weight: bold;}#isi .text{font-size: 12px;}#nav .text{color:#FFFFFF; font-size: 12px ; font-weight: bold;}#nav .text-orange{color:#e24912; font-size: 12px ; font-weight: bold;}#nav .arrow-orange{color:#e24912; font-size: 12px; font-weight: bold;}#nav .arrow-black{color:#000000; font-size: 12px; font-weight: bold;}#isibottom {font-weight: bold; font-size: 13px ;}#content-wrapper {width: 100%; clear:both; background: #fff;}

Cancer Network presents exclusive coverage from the annual American Society of Clinical Oncology (ASCO) Breast Cancer Symposium. Check out the stories below for write-ups of the most important information to come out of this year's event.

Given their greater convenience and, in most cases, decreased costs, APBI and AWBI are becoming increasingly popular alternatives to conventional WBI for early-stage breast cancer patients who desire BCT. However, given the protracted time to local recurrence and complications following BCT, definitive results from randomized clinical trials comparing conventional WBI vs AWBI or APBI are limited.

CML Partnership 091012d

You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.

CML Partnership 091012c

You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.

I have come to the conclusion that a successful systematic approach to earlier transitions from disease-directed cancer therapy to end-of-life and palliative care can only come from better communication in the context of more trusting relationships.

Disclaimer

The advice offered in this ethical consultation feature is based solely on the information supplied by readers, and is offered without benefit of a detailed patient history or physical or laboratory findings. The information is offered as a discussion of ethical issues and is not intended to be medical or legal advice and, therefore, should not be considered complete or used in place of a formal ethics consultation or in place of seeking advice from your ethics committee, legal counsel, or other available resources. One should never disregard or change medical advice or delay in providing it because of something that appears here. The opinions expressed here are only those of the author and do not reflect the viewpoint of ONCOLOGY.

Would it not be advantageous for people fighting what I call the “vile coward” to take a break from its ugly face? With nothing but the best intentions in mind, I hereby proclaim that all patients have permission to take a vacation from cancer, to schedule a time where cancer is not allowed in the door.

The cost of cancer treatment has at least doubled since 1987 and there does not appear to be any hint that cancer care costs will decline. In this podcast we discuss the reasons for the increase in costs, as well as the ethics of cancer care cost containment.